Research by UMass Chan Medical School scientists Sharon Cantor, Ph.D., and Jenna M. Whalen, Ph.D., poses a new explanation ...

Multidrug resistance in cancer can be overcome by combining a drug that blocks a key enzyme with another anticancer drug, ...

Colorectal cancer (CRC) is one of the most common and deadly cancers worldwide, accounting for nearly 10% of all cancer cases ...

Melanoma is one of the most aggressive skin cancers, with over 300,000 new cases reported worldwide each year. In Europe, the ...

Lugano, Switzerland, 24 February 2025 – The ESMO Targeted Anticancer Therapies Congress 2025 will showcase state-of-the-art and the latest advancements in new drug development, with focus on new ...

With a PhD in Genetics and Genomics, Niki Spahich channels her infectious disease research and science communication experiences into her role as the manager of The Scientist's Creative Services team.

The global market for anticancer monoclonal antibodies (MAbs) was valued at approximately USD $$ billion in 2022 and is projected to exhibit a robust growth rate of over $% during the forecast period ...

A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell. The work, published Jan. 29 in Nature Communications, reveals a new signaling ...

Cosmos Health (COSM) has secured buy-out rights and exclusive licensing for two patented anticancer drugs targeting, among others, prostate, ovarian, and colorectal cancers. Both of these ...

Colorectal cancer (CRC) is one of the most prevalent types of cancer and has a high mortality rate globally. Oral ...

Short chains of amino acids can form drug delivery nanoparticles and boost the properties of potential medicines ...

Indian pharma eyes anticancer research investment as drug innovation to propel future growth: Nandita Vijayasimha, Bengaluru Wednesday, February 5, 2025, 08:00 Hrs [IST] Indian ph ...